Cyclosporin A inhibits cardiac hypertrophy and enhances cardiac dysfunction during postinfarction failure in rats

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 278, Issue 6 47-6, 2000, Pages

  Øie, Erik ^a   Bjørnerheim, Reidar ^a   Clausen, Ole Petter F ^a   Attramadal, Havard ^a,b  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Calcineurin; Heart failure; Myocardium

Indexed keywords

CALCINEURIN; CYCLOSPORIN A; ENDOTHELIN 1; RENIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM CELL LEVEL; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG INHIBITION; GENE EXPRESSION; HEART DISEASE; HEART FUNCTION; HEART VENTRICLE HYPERTROPHY; MALE; NONHUMAN; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION;

EID: 0033921549     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.2000.278.6.h2115     Document Type: Article

References (28)

1. Åsberg A, Christensen H, Hartmann A, and Berg KJ. Diltiazem modulates cyclosporin A induced renal hemodynamic effects but not its effect on plasma endothelin-1. Clin Transplant 12: 363-370, 1998.
2. Braun-Dullaeus RC, Feussner M, Walker G, Tillmanns H, and Haberbosch W. Comparison of in vitro cardiovascular function with in vivo echocardiographic assessment after long-term administration of cyclosporine to rats. J Cardiovasc Pharmacol 31: 828-832, 1998.
3. Chien KR, Zhu H, Knowlton KU, Miller-Hance W, van-Bilsen M, O'Brien T, and Evans SM. Transcriptional regulation during cardiac growth and development. Annu Rev Physiol 55: 77-95, 1993.
4. Colucci WS. Molecular and cellular mechanisms of myocardial failure. Am J Cardiol 80: 15L-25L, 1997.
5. 2+ oscillations. Science 279: 227-230, 1998.
6. Ding B, Price RL, Borg TK, Weinberg EO, Halloran PF, and Lorell BH. Pressure overload induces severe hypertrophy in mice treated with cyclosporine, an inhibitor of calcineurin. Circ Res 84: 729-734, 1999.
7. 2+ response amplitude and duration. Nature 386: 855-858, 1997.
8. Dunn SE, Burns JL, and Michel RN. Calcineurin is required for skeletal muscle hypertrophy. J Biol Chem 274: 21908-21912, 1999.
9. Flanagan WM, Corthesy B, Bram RJ, and Crabtree GR. Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A. Nature 352: 803-807, 1991.
10. Gruver CL, DeMayo F, Goldstein MA, and Means AR. Targeted developmental overexpression of calmodulin induces proliferative and hypertrophie growth of cardiomyocytes in transgenic mice. Endocrinology 133: 376-388, 1993.
11. Hasegawa K, Lee SJ, Jobe SM, Markham BE, and Kitsis RN. cis-Acting sequences that mediate induction of beta-myosin heavy chain gene expression during left ventricular hypertrophy due to aortic constriction. Circulation 96: 3943-3953, 1997.
12. Jurado F, Bellon JM, Pareja JA, Golitsin A, Millan L, Pascual G, and Bujan J. Effects of ischaemia-reperfusion and cyclosporin-A on cardiac muscle ultrastructure. Histol Histopathol 13: 761-774, 1998.
13. Luo Z, Shyu KG, Gualberto A, and Walsh K. Calcineurin inhibitors and cardiac hypertrophy. Nat Med 4: 1092-1093, 1998.
14. Meguro T, Hong C, Asai K, Takagi G, McKinsey TA, Olson EN, and Vatner SF. Cyclosporine attenuates pressure-overload hypertrophy in mice while enhancing susceptibility to decompensation and heart failure. Circ Res 84: 735-740, 1999.
15. Mende U, Kagen A, Cohen A, Aramburu J, Schoen FJ, and Neer EJ. Transient cardiac expression of constitutively active Gαq leads to hypertrophy and dilated cardiomyopathy by calcineurin-dependent and independent pathways. Proc Natl Acad Sci USA 95: 13893-13898, 1998.
16. Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, Grant SR, and Olson EN. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 93: 215-228, 1998.
17. Morgan HE, Gordon EE, Kira Y, Chua HL, Russo LA, Peterson CJ, McDermott PJ, and Watson PA. Biochemical mechanisms of cardiac hypertrophy. Annu Rev Physiol 49: 533-543, 1987.
18. Musaro A, McCullagh KJ, Naya FJ, Olson EN, and Rosenthal N. IGF-1 induces skeletal myocyte hypertrophy through calcineurin in association with GATA-2 and NF-ATc1. Nature 400: 581-585, 1999.
19. Øie E, Bjørnerheim R, Grøgaard HK, Kongshaug H, Smiseth OA, and Attramadal H. ET-receptor antagonism, myocardial gene expression, and ventricular remodeling during CHF in rats. Am J Physiol Heart Circ Physiol 275: H868-H877, 1998.
20. Øie E, Vinge LE, Tønnessen T, Grøgaard HK, Kjekshus H, Christensen G, Smiseth OA, and Attramadal H. Transient, isopeptide-specific induction of myocardial endothelin-1 mRNA during congestive heart failure in rats. Am J Physiol Heart Circ Physiol 273: H1727-H1736, 1997.
21. Ono K, Matsumori A, Shioi T, Furukawa Y, and Sasayama S. Cytokine gene expression after myocardial infarction in rat hearts: possible implication in left ventricular remodeling. Circulation 98: 149-156, 1998.
22. Schultz JE, Witt SA, Nieman ML, Reiser PJ, Engle SJ, Zhou M, Pawlowski SA, Lorenz JN, Kimball TR, and Doetschman T. Fibroblast growth factor-2 mediates pressure-induced hypertrophie response. J Clin Invest 104: 709-719, 1999.
23. Schwartz K and Mercadier JJ. Molecular and cellular biology of heart failure. Curr Opin Cardiol 11: 227-236, 1996.
24. Selye H, Bajusz E, Grasso S, and Mendell P. Simple techniques for the surgical occlusion of coronary vessels in the rat. Angiology 11: 398-407, 1960.
25. 2+-dependent calcineurin signalling pathway. Nature 400: 576-581, 1999.
26. Sussman MA, Lim HW, Gude N, Taigen T, Olson EN, Robbins J, Colbert MC, Gualberto A, Wieczorek DF, and Molkentin JD. Prevention of cardiac hypertrophy in mice by calcineurin inhibition. Science 281: 1690-1693, 1998.
27. White HD, Norris RM, Brown MA, Brandt PW, Whitlock RM, and Wild CJ. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 76: 44-51, 1987.
28. Zhang W, Kowal RC, Rusnak F, Sikkink RA, Olson EN, and Victor RG. Failure of calcineurin inhibitors to prevent pressure-overload left ventricular hypertrophy in rats. Circ Res 84: 722-728, 1999.